Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 878-888

  Donmez, Baris Ozgur ^a   Ozdemir, Semir ^b   Sarikanat, Mehmet ^c   Yaras, Nazmi ^b   Koc, Pinar ^d   Demir, Necdet ^a   Karayalcin, Binnur ^a   Oguz, Nurettin ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c EGE UNIVERSITY   (Turkey)

^d FIRAT UNIVERSITY   (Turkey)

Author keywords

Angiotensin; Biomechanics; Bone; Osteoporosis; Ovariectomy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; LOSARTIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FORCE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; QUANTITATIVE ANALYSIS; RAT; SCANNING ELECTRON MICROSCOPY; TENSILE STRENGTH; TRABECULAR BONE; TREATMENT DURATION; YOUNG MODULUS;

EID: 84867688277     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70882-4     Document Type: Article

References (44)

1. Bagi CM, Mecham M, Weiss J, Miller SC: Comparative morphometric changes in rat cortical bone following ovariectomy and/or immobilization. Bone, 1993, 14, 877-883. (Pubitemid 24012698)
2. Bandow K, Nishikawa Y, Ohnishi T, Kakimoto K, Soejima K, Iwabuchi S, Kuroe K et al.: Low-intensity pulsed ultrasound (LIPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor. J Cell Physiol, 2007, 211, 392-398. (Pubitemid 46580093)
3. Bonnet N, Benhamou CL, Malaval L, Goncalves C, Vico L, Eder V, Pichon C et al.: Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol, 2008, 217, 819-827.
4. Boyle P, Leon ME, Autier P: Epidemiology of osteoporosis. J Epidemiol Biostat, 2001, 6, 185-192. (Pubitemid 33134085)
5. Broulik PD, Tesar V, Zima T, Jirsa M: Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res, 2001, 50, 353-358. (Pubitemid 32821681)
6. Burr DB: Osteoporosis and fracture risk: bone matrix quality. J Musculoskelet Neuronal Interact, 2002, 2, 525-526.
7. Comelekoglu U, Bagis S, Yalin S, Ogenler O, Yildiz A, Sahin NO, Oguz I et al.: Biomechanical evaluation in osteoporosis: ovariectomized rat model. Clin Rheumatol, 2007, 26, 380-384. (Pubitemid 46486971)
8. Cummings SR, Black DM, Rubin SM: Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med, 1989, 149, 2445-2448. (Pubitemid 19283200)
9. Currey JD: Physical characteristics affecting the tensile failure properties of compact bone. J Biomech, 1990, 23, 837-844.
10. Duarte PM, Goncalves PF, Sallum AW, Sallum EA, Casati MZ, Humberto Nociti F, Jr.: Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodontal Res, 2004, 39, 107-110. (Pubitemid 39090091)
11. Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med, 1998, 338, 736-746.
12. Egermann M, Goldhahn J, Schneider E: Animal models for fracture treatment in osteoporosis. Osteoporos Int, 2005, 16, Suppl 2, S129-S138. (Pubitemid 46232130)
13. Erben RG, Bromm S, Stangassinger M: Short-term prophylaxis against estrogen depletion-induced bone loss with calcitriol does not provide long-term beneficial effects on cancellous bone mass or structure in ovariectomized rats. Osteoporos Int, 1998, 8, 82-91. (Pubitemid 28085489)
14. Faulkner KG: Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res, 2000, 15, 183-187.
15. Flieger J, Karachalios T, Khaldi L, Raptou P, Lyritis G: Mechanical stimulation in the form of vibration prevents postmenopausal bone loss in ovariectomized rats. Calcif Tissue Int, 1998, 63, 510-514. (Pubitemid 28531801)
16. Folwarczna J, Zych M, Trzeciak HI: Effects of curcumin on the skeletal system in rats. Pharmacol Rep, 2010, 62, 900-909.
17. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY: Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int, 2006, 79, 262-272. (Pubitemid 44673720)
18. Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S: Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J Endocrinol, 1998, 156, 543-550. (Pubitemid 28131472)
19. Han SM, Szarzanowicz TE, Ziv I: Effect of ovariectomy and calcium deficiency on the ultrasound velocity, mineral density and strength in the rat femur. Clin Biomech (Bristol, Avon), 1998, 13, 480-484. (Pubitemid 28442181)
20. Hart KJ, Shaw JM, Vajda E, Hegsted M, Miller SC: Swim-trained rats have greater bone mass, density, strength, and dynamics. J Appl Physiol, 2001, 91, 1663-1668. (Pubitemid 32900357)
21. Hatton R, Stimpel M, Chambers TJ: Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol, 1997, 152, 5-10. (Pubitemid 27026382)
22. Hayirlioglu A, Gokaslan H, Andac N: The effect of bilateral oophorectomy on bone mineral density. Rheumatol Int, 2006, 26, 1073-1077. (Pubitemid 44450840)
23. Hiruma Y, Inoue A, Hirose S, Hagiwara H: Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun, 1997, 230, 176-178. (Pubitemid 27210267)
24. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, Inagami T et al.: Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem, 2009, 284, 4857-4864.
25. Kaczmarczyk-Sedlak I, Zych M, Rotko K, Sedlak L: Effects of thalidomide on the development of bone damage caused by prednisolone in rats. Pharmacol Rep, 2012, 64, 386-395.
26. Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J: Effects of angiotensin II on bone cells in vitro. J Cell Physiol, 1998, 175, 89-98. (Pubitemid 28101975)
27. Lavoie JL, Sigmund CD: Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology, 2003, 144, 2179-2183. (Pubitemid 36629863)
28. Li YQ, Ji H, Shen Y, Ding LJ, Zhuang P, Yang YL, Huang QJ: Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. Can J Physiol Pharmacol, 2009, 87, 51-55.
29. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, Cui TX et al.: Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension, 2002, 40, 451-457; discussion 48-50.
30. Lynn H, Kwok T, Wong SY, Woo J, Leung PC: Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone, 2006, 38, 584-588.
31. Martel C, Picard S, Richard V, Belanger A, Labrie C, Labrie F: Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol, 2000, 74, 45-56.
32. Meunier PJ: Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int J Clin Pract, 1999, 53, 122-129.
33. Osterman T, Lauren L, Kuurtamo P, Hannuniemi R, Isaksson P, Kippo K, Peng Z et al.: The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J Pharmacol Exp Ther, 1998, 284, 312-316. (Pubitemid 28109561)
34. Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Phipps RJ, Nakamura T: Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. J Bone Miner Metab, 2004, 22, 404-414. (Pubitemid 39248835)
35. Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, Sigmund CD: Local production of angiotensin II in the subfornical organ causes elevated drinking. J Clin Invest, 2007, 117, 1088-1095. (Pubitemid 46556765)
36. Sastry TP, Chandrsekaran A, Sundaraseelan J, Ramasastry M, Sreedhar R: Comparative study of some physicochemical characteristics of osteoporotic and normal human femur heads. Clin Biochem, 2007, 40, 907-912. (Pubitemid 47077416)
37. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T et al.: Angiotensin II accelerates osteoporosis by activating osteoclasts. Faseb J, 2008, 22, 2465-2475. (Pubitemid 351948664)
38. Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M: The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord, 2009, 10, 66.
39. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, Nahmias C et al.: Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension, 2002, 39, 41-45. (Pubitemid 34098086)
40. Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ et al.: Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc, 2004, 52, 1479-1486. (Pubitemid 39209595)
41. Turner CH: Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int, 2002, 13, 97-104. (Pubitemid 34241029)
42. Turner CH, Rho J, Takano Y, Tsui TY, Pharr GM: The elastic properties of trabecular and cortical bone tissues are similar: results from two microscopic measurement techniques. J Biomech, 1999, 32, 437-441. (Pubitemid 29156711)
43. Wiens M, Etminan M, Gill SS, Takkouche B: Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med, 2006, 260, 350-362. (Pubitemid 44370908)
44. Yalin S, Sagir O, Comelekoglu U, Berkoz M, Eroglu P: Strontium ranelate treatment improves oxidative damage in osteoporotic rat model. Pharmacol Rep, 2012, 64, 396-402.